David Kok

Long-term Survival with 18-Fluorodeoxyglucose Positron Emission Tomography-directed Therapy in Non-small Cell Lung Cancer with Synchronous Solitary Brain Metastasis.

S Newman, N Bucknell, M Bressel, P Tran, BA Campbell, S David, N Haghighi, GG Hanna, D Kok, M MacManus, C Phillips, N Plumridge, M Shaw, A Wirth, G Wheeler, D Ball, S Siva

Journal article  |  2021  |  Comparative Haematology International

AIMS: At diagnosis, <1% of patients with non-small cell lung cancer (NSCLC) have synchronous solitary brain metastasis (SSBM). In ..

The changing paradigm of managing Merkel cell carcinoma in Australia: An expert commentary

David L Kok, Annie Wang, Wen Xu, Margaret ST Chua, Alexander Guminski, Michael Veness, Julie Howle, Richard Tothill, Ganessan Kichendasse, Michael Poulsen, Shahneen Sandhu, Gerald Fogarty

Journal article  |  2020  |  Asia Pacific Journal of Clinical Oncology

High-resolution MRI demonstrates that more than 90% of small intracranial melanoma metastases develop in close relationship to the leptomeninges

Arian Lasocki, Chloe Khoo, Peter KH Lau, David L Kok, Grant A McArthur

Journal article  |  2020  |  Neuro-Oncology

BACKGROUND: Despite classic teaching that intracranial metastases typically arise at the gray-white matter junction, small intracr..

Post-operative stereotactic radiosurgery following excision of brain metastases: A systematic review and meta-analysis

Zarique Z Akanda, Wei Hong, Sofia Nahavandi, Neda Haghighi, Claire Phillips, David L Kok

Journal article  |  2020  |  Radiotherapy and Oncology

BACKGROUND: Following the resection of brain metastases, Stereotactic Radiosurgery (SRS) to the post-operative surgical cavity has..

Neoadjuvant Stereotactic Radiosurgery: a Further Evolution in the Management of Brain Metastases

Cristian Udovicich, Claire Phillips, David L Kok, Damien Tange, Nikki M Plumridge, Roshan S Prabhu, Neda Haghighi

Journal article  |  2019  |  Current Oncology Reports

A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC -X Trial).

Maria Gonzalez, Angela M Hong, Matteo S Carlino, Victoria Atkinson, Wei Wang, Serigne Lo, Michael Paul Brown, Matthew C Foote, Mark B Pinkham, Hien Le, Daniel E Roos, Monica Osorio, Neda Haghighi, David Kok, Michael A Postow, Grant A McArthur, Alexander M Menzies, Georgina V Long

Conference Proceedings  |  2019  |  Journal of Clinical Oncology

Long-term survival with FDG-PET directed therapy in NSCLC with synchronous solitary brain metastasis

SJ Newman, N Bucknell, M Bressel, P Tran, B Campbell, N Haghighi, D Kok, M MacManus, C Phillips, M Shaw, A Wirth, G Wheeler, D Ball, S Siva

Conference Proceedings  |  2019  |  Radiotherapy and Oncology

Iatrogenic subcutaneous metastasis from WHO Grade I intracranial meningioma

David L Kok, Shona Hendry, Beatriz Alvarez

Journal article  |  2018  |  Journal of Clinical Neuroscience

Adding colour to cancer: The art, science and education trifecta

Sathana Dushyanthen, Michelle Barrett, Grant McArthur, David Kok

Conference Proceedings  |  2018  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

New Era in the Management of Melanoma Brain Metastases.

Hussein A Tawbi, Celine Boutros, David Kok, Caroline Robert, Grant McArthur

Book Chapter  |  2018  |  American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

The remarkable advances in the systemic therapy of metastatic melanoma have now extended the 1-year overall survival rate from 25%..